Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due
to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose
blood cultures are sterilized after 72 hours by 15% relative to vancomycin and would improve
treatment safety.
Hypothesis: for MRSA nosocomial or healthcare related bacteriemia treatment, the use of
daptomycin versus vancomycin would increase by 15% the proportion of patients with sterilized
blood cultures at 72 hours and would increase the treatment safety.
Primary objective: To study the efficacy of daptomycin compared to vancomycin on the
sterilization of blood cultures after 72 hours of therapy.